Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms
aDivision of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School bHarvard School of Public Health, Boston, Massachusetts cDivision of Infectious Diseases and Department of Medicine, Stanford University School of Medicine, Stanford, California dAssociates of Cape Cod, East Falmouth, Massachusetts, USA eSchool of Medicine, University College Dublin, Dublin, Ireland fDivision of Infectious Diseases and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. *Current affiliation: Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.AIDS (London, England) (Impact Factor: 5.55). 03/2013; 27(6):967-972. DOI: 10.1097/QAD.0b013e32835cb646
OBJECTIVE:: The objective of this study was to define the test characteristics of plasma beta-glucan for diagnosis of Pneumocystis jirovecii pneumonia (PCP) in AIDS patients with respiratory symptoms. DESIGN:: Analysis of baseline blood samples in a randomized strategy study of patients with acute opportunistic infections, limited to participants with respiratory symptoms. METHODS:: Participants in the 282-person ACTG A5164 trial had baseline plasma samples assayed for beta-glucan testing. As part of A5164 trial, two study investigators independently adjudicated the diagnosis of PCP. Respiratory symptoms were identified by investigators from a list of all signs and symptoms with an onset or resolution in the 21 days prior to or 14 days following study entry. Beta-glucan was defined as positive if at least 80 pg/ml and negative if less than 80 pg/ml. RESULTS:: Of 252 study participants with a beta-glucan result, 159 had at least one respiratory symptom, 139 of whom had a diagnosis of PCP. The sensitivity of beta-glucan for PCP in participants with respiratory symptoms was 92.8% [95% confidence interval (CI) 87.2-96.5], and specificity 75.0% (95% CI 50.9-91.3). Among 134 individuals with positive beta-glucan and respiratory symptoms, 129 had PCP, for a positive predictive value of 96.3% (95% CI 91.5-98.8). Fifteen of 25 patients with a normal beta-glucan did not have PCP, for a negative predictive value of 60% (95% CI 38.7-78.9). CONCLUSION:: Elevated plasma beta-glucan has a high predictive value for diagnosis of PCP in AIDS patients with respiratory symptoms. We propose an algorithm for the use of beta-glucan as a diagnostic tool on the basis of the pretest probability of PCP in such patients.
- AIDS (London, England) 06/2013; 27(10):1679. DOI:10.1097/QAD.0b013e3283620831 · 5.55 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: This study assessed a quantitative PCR (qPCR) assay for Pneumocystis jirovecii quantification in bronchoalveolar lavage (BAL) fluid samples combined with serum (1→3)-β-d-glucan (BG) level detection to distinguish Pneumocystis pneumonia (PCP) from pulmonary colonization with P. jirovecii. Forty-six patients for whom P. jirovecii was initially detected in BAL fluid samples were retrospectively enrolled. Based on clinical data and results of P. jirovecii detection, 17 and 29 patients were diagnosed with PCP and colonization, respectively. BAL fluid samples were reassayed using a qPCR assay targeting the mitochondrial large subunit rRNA gene. qPCR results and serum BG levels (from a Fungitell kit) were analyzed conjointly. P. jirovecii DNA copy numbers were significantly higher in the PCP group than in the colonization group (1.3 × 107 versus 3.4 × 103 copies/μl, P < 0.05). A lower cutoff value (1.6 × 103 copies/μl) achieving 100% sensitivity for PCP diagnosis and an upper cutoff value (2 × 104 copies/μl) achieving 100% specificity were determined. Applying these two values, 13/17 PCP patients and 19/29 colonized patients were correctly assigned to their patient groups. For the remaining 14 patients with P. jirovecii DNA copy numbers between the cutoff values, PCP and colonization could not be distinguished on the basis of qPCR results. Four of these patients who were initially assigned to the PCP group presented BG levels of ≥100 pg/ml. The other 10 patients, who were initially assigned to the colonization group, presented BG levels of <100 pg/ml. These results suggest that the combination of the qPCR assay, applying cutoff values of 1.6 × 103 and 2 × 104 copies/μl, and serum BG detection, applying a 100 pg/ml threshold, can differentiate PCP and colonization diagnoses.Journal of clinical microbiology 07/2013; 51(10). DOI:10.1128/JCM.01554-13 · 3.99 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Invasive fungal infections have increased worldwide and represent a threat for immunocompromised patients, including those who are HIV infected, recipients of solid organ and stem cell transplants, and patients receiving immunosuppressive therapies. High mortality rates and difficulties in early diagnosis characterise pulmonary fungal infections. In this chapter, invasive pulmonary aspergillosis, cryptococcosis and Pneumocystis jirovecii pneumonia have been reviewed, focusing on clinical aspects and therapeutic management. Although new compounds have become available in recent years (e.g. amphotericin B lipid formulations, third-generation azoles and echinocandins), new diagnostic tools and careful therapeutic management are mandatory to ensure an early appropriate targeted treatment, which is the key to a successful conservative approach in respiratory fungal infections.European Respiratory Monograph 09/2013; 61(61):37-49. DOI:10.1183/1025448x.10040412
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.